Related Experiment Videos
Cytarabine dose for acute myeloid leukemia
Bob Löwenberg1, Thomas Pabst, Edo Vellenga
1Erasmus University Medical Center, Department of Hematology (L413), P.O. Box 2040, 3000 CA Rotterdam, the Netherlands. b.lowenberg@erasmusmc.nl
The New England Journal of Medicine
|March 18, 2011
Summary
Intermediate-dose cytarabine (ara-C) offers similar acute myeloid leukemia (AML) treatment outcomes to high-dose ara-C but with significantly less toxicity. This study suggests maximal antileukemic effects are achieved at lower doses, indicating a plateau in the dose-response relationship.
Area of Science:
- Oncology
- Hematology
- Clinical Pharmacology
Background:
- Cytarabine (ara-C) is a cornerstone in acute myeloid leukemia (AML) treatment.
- High-dose ara-C improves survival but is associated with significant toxicity.
- Optimal intermediate dosing of ara-C for AML induction remains underexplored.
Purpose of the Study:
- To compare the efficacy and safety of intermediate-dose versus high-dose cytarabine induction regimens in newly diagnosed AML patients.
- To evaluate the dose-response relationship of cytarabine in AML treatment.
Main Methods:
- A randomized trial comparing intermediate-dose (200-1000 mg/m²) and high-dose (1000-2000 mg/m²) cytarabine induction regimens in adult AML patients.
- Assessment of complete remission rates, survival outcomes, and treatment-related toxicities.
- Consolidation therapy or stem-cell transplantation followed for patients achieving complete response.
Main Results:
- No significant differences in complete remission rates (80% vs. 82%), 5-year event-free survival (34% vs. 35%), or overall survival (40% vs. 42%) between intermediate- and high-dose groups.
- High-dose cytarabine was associated with increased grade 3/4 toxicities, prolonged hospitalization, and delayed hematologic recovery.
- No clear benefit of high-dose cytarabine was observed across different prognostic subgroups.
Conclusions:
- Intermediate-dose cytarabine induction achieves maximal antileukemic effects in AML, similar to high-dose regimens.
- High-dose cytarabine offers no additional therapeutic benefit and leads to excessive toxicity.
- A plateau in the cytarabine dose-response relationship suggests lower doses may be sufficient for optimal outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...